HonorStocks Biotech Gold Oil Mining China Asian MENU
Biotech Gold Oil Mining China Asian
Find Tomorrow's Winners Today

Stock technical analysis
Rating Flag Rating Flag Rating Flag Rating Flag Rating Flag
sell neutral buy
Akebia Therapeutics, Inc. (AKBA)
3.18  -0.1  (-3.05%) 10-25 06:52
Open: 3.3442 High: 4.18
Pre.close: 3.28 Low: 3.04
Volume: 21,311,601 Ave vol: 6,633,437
52w High: 13.71 52w Low: 2.34
MA(50): 2.904 MA(200): 8.873
EPS: -3.063 P/E Ratio: 0
Company profile
Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Website: https://akebia.com/
Market Cap (M): 456
Shares Out (M): 143
Akebia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with kidney disease. The company is headquartered in Cambridge, Massachusetts and currently employs 325 full-time employees. The firm focuses on the development and commercialization of therapeutics based on hypoxia-inducible factor (HIF) biology. The firm's lead product candidate, vadadustat, is indicated for the treatment of anemia in chronic kidney disease (CKD). The company is involved in developing vadadustat as an oral therapy. The firm's vadadustat is a HIF-prolyl-hydroxylase (HIF-PH) inhibitor in Phase III development for the treatment of anemia of CKD. In addition to vadadustat, the Company is engaged in developing a HIF-based portfolio of product candidates that target serious diseases of unmet need. Its portfolio includes product candidates developed internally, such as AKB-6899, as well as in-licensed product candidates, including AKB-5169. AKB-5169 is a preclinical compound in development as an oral treatment for inflammatory bowel disease (IBD).
Technical analysis
Overall: Neutral
MA: Bearish MACD: Bullish
KDJ: Bearish RSI: Bearish
Target 1: 4.06 Target 2: 4.88
Resist 1: 3.48 Resist 2: 4.18
Support 1: 2.34 Support 2: 1.95
Company key metrics
Revenue per Share: 0.0028
Net Income per Share: -0.0024
Cash per Share: 0.0012
Book Value per Share: 0.0033
Price to Sales: 2661.2496
Price to Book Value: 2258.4052
Earnings Yield: -0.0003
Dividend Yield: 0
Debt to Equity: 0.9536
Debt to Assets: 0.4881
Financial analysis
Price to Book Value: Outperform
Return on Assets: Underperform
Return on Equity: Underperform
Discounted cash flow: Outperform
Price to Earnings: Underperform
Debt to Equity: Outperform
Stock Charts

HonorStocks, Find Tomorrow's Winners Today

©HonorStocks.com | U.S. stock markets, stock quotes and stock analysis. Data and information is provided for informational purposes only, is not intended for trading purposes and is not investment advice. Neither HonorStocks.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. Market data provided by: IEX and Financial Modeling Prep

Privacy Policy: Third parties, including Google, may be placing and reading cookies on your browsers, or other methods to collect information as a result of ad serving on this website. Google's use of advertising cookies enables it and its partners to serve ads to you based on your visit to this site and/or other sites on the Internet. You may opt out of personalized advertising by visiting Ads Settings. If you choose to use this website, you agree to the collection and use of information in relation to this policy. The information collected is used for providing and improving the ads Service. We will not use or share information with anyone, and we do not store any data from users.